Levalbuterol tartrate

製品コードS3153 バッチS315301

化学情報

	Synonyms	Levosalbutamol tartrate	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₃₀H₄₈N₂O₁₂
	分子量	628.71	CAS No.	661464-94-4
Solubility (25°C)*	体外	DMSO	100 mg/mL (159.05 mM)
		Water	100 mg/mL (159.05 mM)
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Levalbuterol tartrate(Levosalbutamol tartrate) is a relatively selective beta2-adrenergic receptor agonist used for the treatment of asthma.
in vivo	Racemic albuterol (7.5 mg, bid) results in a greater improvement in their forced expiratory volume in 1 second (FEV1) as well as in their asthma scores after 1 hour of continuous treatment compared to the Levalbuterol (3.75 mg, bid) administration in children with asthma. The greater improvement in asthma scores is maintained after the second hour of continuous therapy in the racemic albuterol group but not for forced expiratory volume in 1 second (FEV1) measurements. ^[1] Levalbuterol (1.25 mg) requires significantly fewer median total nebulizations and scheduled nebulizations compared with those in the racemic albuterol (2.5 mg) group in patients with asthma or chronic obstructive pulmonary disease (COPD). Disease symptom assessment and subject general well-being score scores improves significantly from baseline in both levalbuterol (1.25 mg) and racemic albuterol (2.5 mg) treatment groups, and beta-mediated adverse effects mean scores are significantly greater with levalbuterol versus racemic albuterol. ^[2]

製品説明

Levalbuterol tartrate(Levosalbutamol tartrate) is a relatively selective beta2-adrenergic receptor agonist used for the treatment of asthma.

in vivo

Racemic albuterol (7.5 mg, bid) results in a greater improvement in their forced expiratory volume in 1 second (FEV1) as well as in their asthma scores after 1 hour of continuous treatment compared to the Levalbuterol (3.75 mg, bid) administration in children with asthma. The greater improvement in asthma scores is maintained after the second hour of continuous therapy in the racemic albuterol group but not for forced expiratory volume in 1 second (FEV1) measurements. ^[1] Levalbuterol (1.25 mg) requires significantly fewer median total nebulizations and scheduled nebulizations compared with those in the racemic albuterol (2.5 mg) group in patients with asthma or chronic obstructive pulmonary disease (COPD). Disease symptom assessment and subject general well-being score scores improves significantly from baseline in both levalbuterol (1.25 mg) and racemic albuterol (2.5 mg) treatment groups, and beta-mediated adverse effects mean scores are significantly greater with levalbuterol versus racemic albuterol. ^[2]

プロトコル(参考用のみ)

参考

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [ J Immunother Cancer, 2024, 12(11)e009805]	PubMed: 39581704

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [ J Immunother Cancer, 2024, 12(11)e009805]

PubMed: 39581704

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。